The use of essential drugs: Eight report of the WHO Expert Committee (WHO, 1998, 84 p.): References

The use of essential drugs: Eight report of the WHO Expert Committee (WHO, 1998, 84 p.)

		(introductory text...)
		WHO Expert Committee on the Use of Essential Drugs - Geneva, 1-5 December 1997
		1. Introduction
		2. Guidelines for establishing a national programme for essential drugs
		3. Criteria for the selection of essential drugs
		4. Guidelines for the selection of pharmaceutical dosage forms
		5. Quality assurance
		6. Reserve anti-infective agents and monitoring of resistance
		7. Applications of the essential drugs concept
		8. Essential drugs and primary health care
		9. Drug donations
		10. Post-registration drug studies
		11. Research and development
		12. Nomenclature
		13. Drug information and educational activities
		14. Selection and updating of lists of essential drugs
		15. Model List of Essential Drugs (tenth list)
		16. Considerations and changes made in revising the model list
		17. Glossary of terms used in the report
		Acknowledgement
		References
		Annex 1. Application form for inclusion in the Model List of Essential Drugs1
		Selected WHO publications of related interest
		Back Cover

References

1. WHO’S revised drug strategy. In: Thirty-ninth World Health Assembly, Geneva, 5-16 May 1986. Volume 1. Resolutions and decisions, and list of participants. Geneva, World Health Organization, 1986 (unpublished document WHA39/1986/REC/1), Annex 5:93-101.

2. Handbook of resolutions and decisions of the World Health Assembly and Executive Board, Volume III, 1985-1986, 1st ed. Geneva, World Health Organization, 1987:22.

3. The use of essential drugs. Seventh report of the WHO Expert Committee. Geneva, World Health Organization, 1997 (WHO Technical Report Series, No. 867).

4. Prophylactic and therapeutic substances. In: Twenty-eighth World Health Assembly, Geneva, 13-30 May 1975. Part 1. Resolutions and decisions, annexes. Geneva, World Health Organization, 1975 (Official Records of the World Health Organization, No. 226), Annex 13:96-110.

5. Handbook of resolutions and decisions of the World Health Assembly and Executive Board, Volume II, 1973-1984. Geneva. World Health Organization, 1985:129.

6. The selection of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1977 (WHO Technical Report Series, No. 615).

7. The selection of essential drugs. Second report of a WHO Expert Committee. Geneva, World Health Organization, 1979 (WHO Technical Report Series, No. 641).

8. The use of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1983 (WHO Technical Report Series, No. 685).

9. The use of essential drugs. Model list of essential drugs (fourth revision). Second report of the WHO Expert Committee. Geneva, World Health Organization, 1985 (WHO Technical Report Series, No. 722).

10. The use of essential drugs. Model list of essential drugs (fifth list). Third report of the WHO Expert Committee. Geneva, World Health Organization, 1988 (WHO Technical Report Series, No. 770).

11. The use of essential drugs. Model list of essential drugs (sixth list). Fourth report of the WHO Expert Committee. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No. 796).

12. The use of essential drugs. Model list of essential drugs (seventh list). Fifth report of the WHO Expert Committee. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 825).

13. The use of essential drugs. Sixth report of the WHO Expert Committee. World Health Organization, 1995 (WHO Technical Report Series, No. 850).

14. International nonproprietary names (INN) for pharmaceutical substances. Cumulative list No. 9. Geneva, World Health Organization, 1996.¹

¹ Further lists of proposed and recommended INNs are issued periodically in WHO drug information.

15. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 823).

16. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-sixth report. Geneva, World Health Organization, 1977 (WHO Technical Report Series, No. 614).

17. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-seventh report. Geneva, World Health Organization, 1980 (WHO Technical Report Series, No. 645).

18. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-eighth report. Geneva, World Health Organization, 1982 (WHO Technical Report Series, No. 681).

19. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-ninth report. Geneva, World Health Organization, 1984 (WHO Technical Report Series, No. 704).

20. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth report. Geneva, World Health Organization, 1987 (WHO Technical Report Series, No. 748).

21. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-first report. Geneva, World Health Organization, 1990 (WHO Technical Report Series, No. 790).

22. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-third report. Geneva, World Health Organization, 1993 (WHO Technical Report Series, No. 834).

23. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization, 1996 (WHO Technical Report Series, No. 863).

24. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth report. Geneva, World Health Organization, in press (WHO Technical Report Series, No. 885).

25. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, Volume III, 1985-1992, 3rd ed. Geneva, World Health Organization, 1993:93-94.

26. The international pharmacopoeia, 3rd ed. Geneva, World Health Organization, Vol. 1, 1979; Vol. 2, 1981; Vol. 3, 1998; Vol. 4, 1994.

27. Basic tests for pharmaceutical substances. Geneva, World Health Organization, 1986.

28. Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms. Geneva, World Health Organization, 1998.

29. Basic tests for pharmaceutical dosage forms. Geneva, World Health Organization, 1991.

30. Counterfeit drugs: report of a WHO/IFPMA workshop, Geneva, 1997. Geneva, World Health Organization, 1997 (unpublished document WHO/DMP/CFD/97; available on request from Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland).

31. Report of a WHO Consultation. Surveillance of Antimicrobial Resistance. Geneva, World Health Organization, 1982 (unpublished document BVI/PHA/ANT/82.2; available on request from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland).

32. WHO Scientific Working Group. Antimicrobial resistance. Bulletin of the World Health Organization, 1983, 61:383-394.

33. The new emergency health kit. Lists of drugs and medical supplies for a population of 10000 persons for 3 months. Geneva, World Health Organization, 1990 (unpublished document DAP/90.1; available on request from Action Programme on Essential Drugs, World Health Organization, 1211 Geneva 27, Switzerland).

34. Emergency relief items. Compendium of basic specifications. Volume 2. Medical supplies and equipment, selected essential drugs, guidelines for drug donations. Copenhagen, United Nations Development Programme Inter-Agency Procurement Services Office (UNDP/IAPSO), 1996.

35. Management of childhood illness. Geneva, World Health Organization, 1995 (unpublished document WHO/CDR/95.14; available on request from Division of Child Health and Development, World Health Organization, 1211 Geneva 27, Switzerland).

36. Ethical criteria for medicinal drug promotion. Geneva, World Health Organization, 1988.

37. Guidelines for drug donations. Geneva, World Health Organization, 1996 (unpublished document WHO/DAP/96.2; available on request from Action Programme on Essential Drugs, World Health Organization, 1211 Geneva 27, Switzerland).

38. Nonproprietary names for pharmaceutical substances. In: Forty-sixth World Health Assembly, Geneva, 3-14 May 1993, volume 1. Resolutions and decisions, annexes. Geneva, World Health Organization, 1993 (unpublished document WHA46/1993/REC/1): 20-21.

39. WHO model prescribing information: drugs used in anaesthesia. Geneva, World Health Organization, 1989.

40. WHO model prescribing information: drugs used in parasitic diseases, 2nd ed. Geneva, World Health Organization, 1995.

41. WHO model prescribing information: drugs used in mycobacterial diseases. Geneva, World Health Organization, 1991 (out of print).

42. WHO model prescribing information: drugs used in sexually transmitted diseases and HIV infection. Geneva, World Health Organization, 1995.

43. WHO model prescribing information: drugs used in skin diseases. Geneva, World Health Organization, 1997.

44. Single Convention on Narcotic Drugs, 1961 with amendments 1972. New York, United Nations, 1972.

45. Convention on Psychotropic Substances, 1971. New York, United Nations, 1977.

46. United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. New York, United Nations, 1991.

47. Gilles HM. Management of severe and complicated malaria. A practical handbook. Geneva, World Health Organization, 1991.

48. Treatment of tuberculosis. Guidelines for national programmes, 2nd ed. Geneva, World Health Organization, 1997 (unpublished document WHO/TB/97.220; available on request from Global Programme on Tuberculosis, World Health Organization, 1211 Geneva 27, Switzerland).

49. Management of patients with sexually transmitted diseases. Report of a WHO Study Group. Geneva, World Health Organization, 1991 (WHO Technical Report Series, No. 810).

50. Cancer pain relief: with a guide to opioid availability, 2nd ed. Geneva, World Health Organization, 1996.

51. Model guidelines for the international provision of controlled medicines for emergency medical care. Geneva, World Health Organization, 1996 (unpublished document WHO/PSA/96.17; available on request from Division of Mental Health and Prevention of Substance Abuse, World Health Organization, 1211 Geneva 27, Switzerland).